<a href="https://laohu8.com/S/SVRA">Savara Inc</a>. Announces Publication of Phase 3 IMPALA-2 Trial Results in NEJM, Highlighting Efficacy of Molgramostim for Autoimmune PAP
Savara Inc. has announced that the results from its Phase 3 IMPALA-2 clinical trial will be published online in the New England Journal of Medicine (NEJM) on August 21, 2025. The trial focused on the use of inhaled molgramostim therapy in patients with autoimmune Pulmonary Alveolar Proteinosis (PAP), a rare respiratory disease. The study, characterized as the largest and longest Phase 3 clinical trial conducted in autoimmune PAP, demonstrated that 48 weeks of daily administration of molgramostim reduced pulmonary surfactant burden and improved pulmonary gas transfer, respiratory health-related quality of life, and patient functionality. The treatment was well tolerated with no notable safety concerns. The manuscript detailing the trial results will be available on the company's website following its publication in NEJM.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250820194710) on August 20, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。